Waters recently surveyed 100 method developers from innovator and generic pharmaceutical companies to better understand their existing challenges and views on Method Lifecycle Management (MLCM). We’ll share with you the top questions and findings from our survey results.
Waters recently partnered with United States Pharmacopeia (USP) experts to host a webinar discussing the upcoming changes in the pending USP General Chapter on chromatography that will provide increased flexibility for gradient methods. Here’s an extended Q&A from the webinar.
“Assuming continuous improvement is a worthy goal, there is every reason to improve validated chromatographic methods if you’re working with the right instrument technology,” says Eric Grumbach of Waters. See what that means for developing and transferring methods for biologic drugs.
Retaining and separating highly polar, water-soluble organic compounds has been a challenge for separations scientists who prefer reversed-phase chromatography as their technique of choice. See how Waters has addressed these analytical challenges with our T3 columns.
Chromatographers sometimes find themselves challenged as they move from analytical to preparative scales. To help gain a higher-level of understanding and knowledge of purification, check out our primer.
With access to multiple mass spectrometry systems of varying degrees of sophistication, Davy Guillarme (University of Geneva, Switzerland) wasn’t actively looking for new mass detection solutions. Nevertheless, the Waters ACQUITY QDa mass detector caught his eye.
Question: When someone says microscale chromatography, what comes to mind? Increased sensitivity? Reduced sample volume? Enhanced MS sampling efficiency? Yes, yes, and yes! You might also say, “finicky,” “slow,” or “only one person in… Read more >
The drug development process requires pharmacokinetic (PK) analysis to be performed as part of safety and efficacy studies in both preclinical species and human subjects. For high-sensitivity bioanalysis, liquid chromatography (LC) coupled to a triple… Read more >
As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?
Recently, Bioanalysis Zone announced that nominations are now being accepted for the New Investigator’s award (formerly the Young Investigators award) which is sponsored by Waters Corporation for the 5th year in a row. This is… Read more >
